Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated over a 12-week double-blind period with up to 12 months of follow-up. The trial design includes a randomized withdrawal phase, allowing researchers to assess both sustained benefit and whether effects depend on continued use. Results from this study will help clarify whether a standardized full-spectrum cannabis extract can serve as a viable, evidence-based option for patients with chronic low back pain who have not responded adequately to conventional treatments.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where conventional pharmacotherapy has demonstrated limited efficacy and tolerability issues. The large sample size (820 participants) and double-blind design with extended follow-up strengthen the validity of efficacy and safety findings, potentially establishing a new therapeutic option for patients who fail or cannot tolerate standard analgesics and NSAIDs. If positive, these results could support regulatory approval and clinical integration of standardized cannabis extracts into evidence-based pain management protocols, particularly for opioid-sparing alternatives.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial adds meaningful data to our limited evidence base for full-spectrum cannabis in chronic low back pain, showing efficacy in a reasonably sized population where conventional options often disappoint patients. However, several factors warrant cautious interpretation: the study appears incomplete in the abstract provided, baseline pain severity and functional outcomes aren’t detailed, and we lack information on whether benefits persist beyond the open-label phase or how this extract compares directly to other cannabinoid formulations or multimodal approaches. The heterogeneity of cannabis products and individual patient responses means that even positive findings in a controlled trial may not directly predict outcomes in diverse clinical populations with varying comorbidities and concurrent medications. For now, if you’re considering recommending or discussing cannabis with CLBP patients, frame it as one option within a broader pain management strategy, ensure clear documentation of the specific product and dosing, and establish realistic expectations that individual response varies considerably and long-term safety data in this indication remains limited.